Orion Infusions (DHA:ORIONINFU) Cash Flow from Operations: BDT66.7 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:ORIONINFU Orion Infusions Ltd DHA:ORIONINFU
71 GF Score
Price BDT224.60
GF Value BDT312.96
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Orion Infusions Cash Flow from Operations?

Orion Infusions DHA:ORIONINFU 71 Cash Flow from Operations is BDT66.7 Mil as of Mar. 2026. GuruFocus rates DHA:ORIONINFU with a GF Score™ of 71/100 and a GF Value™ of BDT312.96 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Mar. 2026, Orion Infusions's Net Income From Continuing Operations was BDT7.2 Mil. Its Depreciation, Depletion and Amortization was BDT4.6 Mil. Its Change In Working Capital was BDT9.4 Mil. Its cash flow from deferred tax was BDT0.0 Mil. Its Cash from Discontinued Operating Activities was BDT0.0 Mil. Its Asset Impairment Charge was BDT0.0 Mil. Its Stock Based Compensation was BDT0.0 Mil. And its Cash Flow from Others was BDT-3.4 Mil. In all, Orion Infusions's Cash Flow from Operations for the three months ended in Mar. 2026 was BDT17.9 Mil.


Orion Infusions  (DHA:ORIONINFU) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Orion Infusions's net income from continuing operations for the three months ended in Mar. 2026 was BDT7.2 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Orion Infusions's depreciation, depletion and amortization for the three months ended in Mar. 2026 was BDT4.6 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Orion Infusions's change in working capital for the three months ended in Mar. 2026 was BDT9.4 Mil. It means Orion Infusions's working capital increased by BDT9.4 Mil from Dec. 2025 to Mar. 2026 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Orion Infusions's cash flow from deferred tax for the three months ended in Mar. 2026 was BDT0.0 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Orion Infusions's cash from discontinued operating Activities for the three months ended in Mar. 2026 was BDT0.0 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Orion Infusions's asset impairment charge for the three months ended in Mar. 2026 was BDT0.0 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Orion Infusions's stock based compensation for the three months ended in Mar. 2026 was BDT0.0 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Orion Infusions's cash flow from others for the three months ended in Mar. 2026 was BDT-3.4 Mil.


Orion Infusions Cash Flow from Operations Related Terms


Orion Infusions Cash Flow from Operations Historical Data

* Premium members only.

The historical data trend for Orion Infusions's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orion Infusions Cash Flow from Operations Chart

Orion Infusions Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.54 45.45 60.67 57.45 26.45

Orion Infusions Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.63 11.18 10.26 27.39 17.88
DHA:ORIONINFU
71GF Score
Orion Infusions Ltd DHA:ORIONINFU
Cash Flow from Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orion Infusions Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Orion Infusions's Cash Flow from Operations for the fiscal year that ended in Jun. 2025 is calculated as:

Orion Infusions's Cash Flow from Operations for the quarter that ended in Mar. 2026 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT66.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Operations of BDT66.7 Mil mean?
Orion Infusions (DHA:ORIONINFU) has a Cash Flow from Operations of BDT66.7 Mil as of Mar. 2026. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for Orion Infusions and its competitors.
Is Orion Infusions' Cash Flow from Operations too high?
Orion Infusions' current Cash Flow from Operations is BDT66.7 Mil. Overall, Orion Infusions has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orion Infusions' Cash Flow from Operations compare to ZTS and UTHR?
Orion Infusions' Cash Flow from Operations of BDT66.7 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Operations for a Drug Manufacturers company?
A good Cash Flow from Operations depends on the Drug Manufacturers industry context. However, Cash Flow from Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Operations mean?
A high Cash Flow from Operations can signal that a stock is expensive relative to its fundamentals. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for Orion Infusions and its competitors. Orion Infusions's current Cash Flow from Operations is BDT66.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Infusions stock overvalued right now?
Based on GuruFocus' analysis, Orion Infusions (DHA:ORIONINFU) is currently considered Modestly Undervalued. The stock's GF Value™ is BDT312.96, compared to a current price of BDT224.60 — trading 28.2% below its estimated fair value. The current Cash Flow from Operations is BDT66.7 Mil. Orion Infusions' overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Operations calculated?
Cash Flow from Operations is calculated from a company's financial statements. For Orion Infusions (DHA:ORIONINFU), the current Cash Flow from Operations is BDT66.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orion Infusions (DHA:ORIONINFU) Overvalued in 2026?

Based on GuruFocus' analysis, Orion Infusions stock appears to be undervalued. The current stock price of BDT224.60 is trading 28.2% below its estimated GF Value™ of BDT312.96. GuruFocus considers Orion Infusions to be Modestly Undervalued.

Key valuation signals for DHA:ORIONINFU:

  • Cash Flow from Operations: BDT66.7 Mil
  • GF Value™: BDT312.96 vs. price of BDT224.60 (28.2% below fair value)
  • GF Score™: 71/100 with 3 warning signs

No single metric tells the full story. See the DHA:ORIONINFU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Orion Infusions Business Description

Address 153-154 Tejgaon Industrial Area, Orion House, Dhaka, BGD, 1208
Orion Infusions Ltd is a pharmaceutical company engaged in the production of various types of intravenous fluids, rehydration solutions, electrolyte solutions, and solutions for acidosis, as well as Ranitidine I.V. infusion and anti-microbial products such as Ciprofloxacin I.V. and Metronidazole I.V. The Company's products include Dextrolac, Dextropac, Dextrosal, Dianak, Electro Dex, Fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the Group operates across several sectors, including pharma and healthcare, power and energy, infrastructure development, real estate, cosmetics and toiletries, consumer products, textiles and garments, and home appliances. Geographically, the Company operates in Bangladesh.
71GF Score

Get the complete analysis for DHA:ORIONINFU

Cash Flow from Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT224.60
Price
BDT312.96
GF Value